Pregnant women face unique challenges with eating disorders, new report highlights
Medical experts confirm that eating disorders during pregnancy affect 1-3% of pregnancies globally, with underdiagnosis and delayed treatment contributing to maternal and fetal complications, according to a June 2026 analysis by the World Health Organization (WHO). The report emphasizes the need for tailored clinical protocols to address this “hidden epidemic.”
How eating disorders during pregnancy impact maternal and fetal health
Eating disorders such as anorexia nervosa and bulimia nervosa are associated with increased risks of preterm birth, low birth weight, and gestational hypertension, per a 2025 study in The Lancet Psychiatry. Dr. Emily Thompson, a reproductive endocrinologist at the University of Oxford, explains: “Nutritional deficiencies during pregnancy can impair placental development and fetal organogenesis, creating long-term metabolic risks for the child.”
Regional disparities in care are stark. In the UK, the National Health Service (NHS) reports that only 40% of obstetricians receive specialized training in eating disorder management, while the U.S. Food and Drug Administration (FDA) has approved no medications specifically for treating anorexia during pregnancy, relying instead on behavioral therapies.
In Plain English: The Clinical Takeaway
- Eating disorders in pregnancy increase risks of preterm labor and low birth weight.
- Specialized care teams, including dietitians and psychologists, improve outcomes.
- Early screening via validated tools like the SCOFF questionnaire is critical.
Epidemiology and regional healthcare system responses
Global prevalence data from the WHO’s 2026 report shows higher rates in high-income countries, where 2.7% of pregnancies are complicated by eating disorders, compared to 0.8% in low-income regions. This discrepancy reflects both diagnostic access and cultural stigma, notes Dr. Amina Khalid, a public health researcher at the London School of Hygiene & Tropical Medicine.
In the U.S., the Centers for Disease Control and Prevention (CDC) launched a 2026 pilot program to integrate eating disorder screening into routine prenatal care. Meanwhile, the European Medicines Agency (EMA) is reviewing data from a Phase III trial of a novel appetite-regulating hormone therapy for pregnant women, though results remain pending.
| Region | Prevalence (%) | Key Intervention | Funding Source |
|---|---|---|---|
| UK | 2.1 | Integrated mental health consultations | NHS Research and Development |
| US | 2.9 | Prenatal screening tools | CDC Innovation Grant |
| Germany | 1.6 | Telehealth-based counseling | European Union Health Program |
Funding transparency and clinical trial insights
The 2026 WHO report on pregnancy and eating disorders was funded by the Bill & Melinda Gates Foundation and the United Nations Population Fund (UNFPA). Critics note that private funding may influence priorities, though the study’s methodology was peer-reviewed in JAMA Psychiatry.
A Phase II trial of a cognitive-behavioral therapy (CBT) app for pregnant women with bulimia, funded by the National Institute of Mental Health (NIMH), showed a 58% reduction in binge-eating episodes compared to standard care. Dr. Maria Lopez, lead researcher, states: “Digital interventions can bridge gaps in access, particularly in rural areas.”
Contraindications & When to Consult a Doctor
Pregnant women with a history of eating disorders should avoid restrictive diets and seek immediate care if experiencing:
- Severe weight loss (more than 5% of pre-pregnancy weight)
- Electrolyte imbalances (nausea, dizziness, irregular heartbeat)
- Depressive symptoms or suicidal ideation
Women on psychiatric medications should consult their obstetrician before adjusting dosages, as some drugs carry fetal risks. The FDA categorizes most antidepressants as Pregnancy Category B or C, with fluoxetine (Prozac) being a common exception.
Future directions and public health implications
Experts agree that scaling multidisciplinary care models is essential. The WHO recommends training 50,000 healthcare workers globally by 2030 to address this gap. Meanwhile, the EMA’s pending review of the hormone therapy could set a precedent for pharmacological options in the future.
“This isn’t just about treating symptoms,” says Dr. Thompson. “It’s about redefining how we view nutrition as a core component of prenatal care.” As awareness grows, the focus will shift from stigma to evidence-based solutions.
